All Access Articles |
- ArriVent BioPharma Prices Public Offering at $19.50 per Share | 2025-07-03 | UNITED STATES
- Positive Interim Data for Firmonertinib in NSCLC Study | 2025-06-23 |
- ArriVent BioPharma Appoints Dr. Merdad Parsey to Board | 2025-04-28 | UNITED STATES
- ArriVent BioPharma Reports Strong Financial Results | 2025-03-03 | UNITED STATES